| Curtis Jay Purser, APRN-CNP | |
|
3001 W Blue Starr Dr, Claremore, OK 74017-2544 | |
| (918) 342-5432 | |
| Not Available |
| Full Name | Curtis Jay Purser |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner - Family |
| Location | 3001 W Blue Starr Dr, Claremore, Oklahoma |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174156525 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | R111354 (Oklahoma) | Primary |
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210505002298 |
News Archive
InSightec Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS), announced that it has received approval from the US Food and Drug Administration to begin a Phase I clinical trial evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor dominant Parkinson's Disease.
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
Studying thousands of people, researchers at The University of Texas M. D. Anderson Cancer Center have documented a 25 percent increased risk of developing one of a number of cancers in first-degree relatives of lung cancer patients who have never smoked compared to families of people who neither smoke nor have lung cancer.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
Survival after a general anaesthetic and within 48 hours of surgery has greatly improved worldwide over the past 50 years, according to the second Article in The Lancet surgery-themed issue.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Curtis Jay Purser, APRN-CNP 3001 W Blue Starr Dr, Claremore, OK 74017-2544 Ph: (918) 342-5432 | Curtis Jay Purser, APRN-CNP 3001 W Blue Starr Dr, Claremore, OK 74017-2544 Ph: (918) 342-5432 |
News Archive
InSightec Ltd, the global leader in MR guided Focused Ultrasound (MRgFUS), announced that it has received approval from the US Food and Drug Administration to begin a Phase I clinical trial evaluating the use of its ExAblate Neuro system for the treatment of patients with tremor dominant Parkinson's Disease.
Mirada Medical, a global leader in Artificial Intelligence software for the treatment of cancer, has announced today further global installations of DLCExpert, the world's first commercially available AI-powered auto contouring software for cancer treatment planning and the only system with over one year of clinically proven use.
Studying thousands of people, researchers at The University of Texas M. D. Anderson Cancer Center have documented a 25 percent increased risk of developing one of a number of cancers in first-degree relatives of lung cancer patients who have never smoked compared to families of people who neither smoke nor have lung cancer.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
Survival after a general anaesthetic and within 48 hours of surgery has greatly improved worldwide over the past 50 years, according to the second Article in The Lancet surgery-themed issue.
› Verified 6 days ago
Megan Diane Rasor, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1201 Parkland Ave, Claremore, OK 74017 Phone: 918-244-9175 | |
Mrs. Carol Sue Carter, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1926 S Highway 66, Claremore, OK 74019 Phone: 918-978-8900 | |
Mrs. Shannon Reavis, ARNP FNP-C Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 21625 E 460 Rd, Claremore, OK 74019 Phone: 918-606-5702 | |
Melissa Nell Gingerich, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1501 N Florence Ave, Claremore, OK 74017 Phone: 918-579-3627 | |
Valerie Mitchell, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1501 N Florence Ave Ste 250, Claremore, OK 74017 Phone: 918-343-8513 | |
Linda A Meredith, NP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3001 W Blue Starr Dr, Claremore, OK 74017 Phone: 918-342-5432 Fax: 918-342-0835 | |
Arlene Maria Ann Siereveld, NP-C Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3001 W Blue Starr Dr, Claremore, OK 74017 Phone: 918-342-5432 Fax: 918-342-0835 |